Creative Medical Technology Holdings Reports Q1 2026 Financial Results with $1.4M Net Loss

Creative Medical Technology Holdings, Inc. reported its financial results for the first quarter of 2026, revealing a net loss of $1.4 million, a decrease from a net loss of $1.6 million in the same period last year. The company did not generate any revenue during the quarter, compared to $3,000 in revenue for the first quarter of 2025. The absence of revenue contributed to a gross loss of $1.8 million, while total operating expenses decreased to approximately $1.46 million from $1.66 million year-over-year, primarily due to reduced research and development costs.

The company's cash position as of March 31, 2026, stood at $5.72 million, down from $7.21 million at the end of 2025. This decline in cash was attributed to net cash used in operating activities, which decreased to $1.32 million from $1.59 million in the prior year, reflecting a 17% reduction in cash outflows. The company also reported cash used in investing activities of $175,000, which included a $125,000 investment in a related entity and a $50,000 investment in a note receivable.

In terms of strategic developments, Creative Medical Technology Holdings has been actively expanding its product offerings and clinical trials. The company is focused on regenerative therapies across various medical fields, including immunotherapy and endocrinology. Notably, the company has received FDA clearance to initiate a Phase I/II clinical trial for its AlloStemSpine® Chronic Lower Back Pain treatment, which is expected to enroll 30 patients. Additionally, the company has made significant advancements in its ImmCelz™ platform, which utilizes reprogrammed immune cells for therapeutic applications.

Operationally, the company has not reported significant changes in customer counts or user statistics, as it continues to develop its clinical programs. The employee headcount remains stable, with no major organizational changes noted in the filing. The company’s focus on research and development remains a critical component of its strategy, with R&D expenses totaling $541,658 for the quarter, down from $743,304 in the previous year. This reduction reflects a strategic shift in resource allocation towards more promising clinical trials.

Looking ahead, Creative Medical Technology Holdings remains optimistic about its future prospects, particularly with ongoing clinical trials and product development initiatives. The company aims to leverage its advancements in regenerative therapies to capture a larger market share in the biotechnology sector. However, it acknowledges the inherent risks associated with its limited operating history and the competitive landscape, which may impact its ability to generate revenue in the near term.